Your session is about to expire
← Back to Search
Study Summary
This trial is being done to learn more about a new substance called BAY2666605 that may help treat advanced cancer by triggering cell death.
- Metastatic Melanoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the upper limit of participants allowed in this experiment?
"Indeed, clinicaltrials.gov displays that this research is still recruiting participants. This experiment was first published on April 15th 2021 and was recently amended on November 14th 2022; 89 individuals need to be recruited from 5 different medical centres."
What objectives has this trial been designed to achieve?
"As stated by the trial's sponsor, Bayer Pharmaceuticals, the primary objective over a 6 month window will be to measure DLTs (dose-limiting toxicities) at each dose level in the dose escalation period. Additionally, secondary outcomes such as DOR (duration of response), DCR (disease control rate), and ORR (objective response rate) will also be examined."
How many institutions are overseeing this clinical research?
"Participants can enroll in this trial via five clinical sites, including South Texas Accelerated Research Therapeutics, LLC (San Antonio), Yale University School of Medicine (New Haven), and Sarah Cannon Development Innovations (Nashville). Additionally, there are two other locations."
Does this research endeavor currently have open slots for participants?
"Affirmative. Clinicaltrials.gov data indicates that, as of November 14th 2022, this medical trial is actively searching for participants; it was originally posted in April 15th 2021. 89 patients need to be recruited from 5 separate sites."
Has BAY2666605 been approved by the US Food and Drug Administration?
"Considering the limited safety and efficacy data, BAY2666605 earned a score of 1 on our team's scale from 1 to 3."
Share this study with friends
Copy Link
Messenger